Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PDGFRA in vascular adventitial MSCs promotes neointima formation in arteriovenous fistula in chronic kidney disease
Ke Song, Ying Qing, Qunying Guo, Eric K. Peden, Changyi Chen, William E. Mitch, Luan Truong, Jizhong Cheng
Ke Song, Ying Qing, Qunying Guo, Eric K. Peden, Changyi Chen, William E. Mitch, Luan Truong, Jizhong Cheng
View: Text | PDF
Research Article Nephrology Stem cells

PDGFRA in vascular adventitial MSCs promotes neointima formation in arteriovenous fistula in chronic kidney disease

  • Text
  • PDF
Abstract

Chronic kidney disease (CKD) induces the failure of arteriovenous fistulas (AVFs) and promotes the differentiation of vascular adventitial GLI1-positive mesenchymal stem cells (GMCs). However, the roles of GMCs in forming neointima in AVFs remain unknown. GMCs isolated from CKD mice showed increased potential capacity of differentiation into myofibroblast-like cells. Increased activation of expression of PDGFRA and hedgehog (HH) signaling were detected in adventitial cells of AVFs from patients with end-stage kidney disease and CKD mice. PDGFRA was translocated and accumulated in early endosome when sonic hedgehog was overexpressed. In endosome, PDGFRA-mediated activation of TGFB1/SMAD signaling promoted the differentiation of GMCs into myofibroblasts, extracellular matrix deposition, and vascular fibrosis. These responses resulted in neointima formation and AVF failure. KO of Pdgfra or inhibition of HH signaling in GMCs suppressed the differentiation of GMCs into myofibroblasts. In vivo, specific KO of Pdgfra inhibited GMC activation and vascular fibrosis, resulting in suppression of neointima formation and improvement of AVF patency despite CKD. Our findings could yield strategies for maintaining AVF functions.

Authors

Ke Song, Ying Qing, Qunying Guo, Eric K. Peden, Changyi Chen, William E. Mitch, Luan Truong, Jizhong Cheng

×

Figure 3

CKD stimulates GMC differentiation into myofibroblasts.

Options: View larger image (or click on image) Download as PowerPoint
CKD stimulates GMC differentiation into myofibroblasts.
(A) GLI1CreERt2 ...
(A) GLI1CreERt2 mice were crossed with mT/mG reporter mice to generate mT/mG/GLI1CreERt2 mice for labeling and tracking GLI1-positive cells. (B) GFP-positive cells were determined by immunostaining. More GFP-positive cells were found in the adventitia of carotid arteries from CKD versus sham Ctl mice. Scale bars: 100 μm. (C) Total RNAs were extracted from GMCs that were isolated from Ctl and CKD mice. CKD increased the mRNA levels of myofibroblast markers. The levels of mRNA expression are presented as folds of Ctl group after normalization to β-actin (n = 3). **P < 0.01 versus Ctls (t test). (D) GMCs isolated from Ctl and CKD mice differentiated into myofibroblasts. For immunofluorescent staining, GMCs were treated with TrueBlack Quencher reagent (40) (Biotium) for 15 minutes to quench GFP before incubating with fibronectin and α-SMA antibodies. Scale bars: 10 μm. CKD, chronic kidney disease; GMC, GLI1-positive mesenchymal stem cell; Ctl, control; α-SMA, α-smooth muscle actin.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts